BMS: Buyer or buyout target?

Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to sell off its ConvaTec wound-care unit for $4.1 billion. Now, it's planning to spin off 10 percent to 20 percent of its Mead Johnson baby formula business in an IPO--a deal that could fetch up to $9.1 billion.

Why the sell-offs? One train of thought: BMS is primping for a suitor. By slenderizing, it's making itself more attractive to a bigger drugmaker--say Pfizer, AstraZeneca, Novartis, or Sanofi-Aventis.

Another train of thought: Bristol could be gathering up cash for a war chest of its own. That would allow BMS to snap up smaller drug companies to shore up its product portfolio.

- check out the item at Seeking Alpha
- see the skinny at Blogging Stocks
- read Jim Cramer's prognostications at The Street

Related Articles:
BMS sources discount chance of Sanofi buyout
Report: Sanofi-Aventis inks preliminary deal for BMS
Patent victory reignites rumors of BMS takeover
Rumor Mill: Is BMS going on the sales block?
Analysts buzzing about possible Bristol-Myers sale

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.